These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Sep 27, 2016ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
- PNT737 currently in Phase 1 clinical trials at the Royal Marsden, London, UK - - Potential to exploit cancer-driving genetic mutations to achieve synthetic lethality - - Broad development...
Aug 12, 2016
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, today reported its financial and...
Jun 6, 2016
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company advancing targeted therapeutics for patients with cancer, today announced interim results from the Wolverine Phase 2 trial of...
Jun 1, 2016
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted therapeutics, today announced it has appointed Dr. Christian Hassig as Senior Vice President,...
May 26, 2016
- Small molecule kinase inhibitor AS-141 positioned for clinical trials in 2017 - - CDC7 is an important regulator of DNA replication and DNA damage response - VANCOUVER, May 26, 2016 /CNW/ -...